

Placement Update and Cleansing Notice

Melbourne, Australia: Bio-Gene Technology Limited (ASX:BGT or 'Bio-Gene' or 'the Company'), is pleased to announce that it has received commitments for an additional \$65,000 from sophisticated investors in addition to the \$2.71m placement announced on 26 May 2026, bringing the total to \$2.775m (**the Placement**).

The placement comprised an issue of fully paid ordinary shares (**Shares**), at an issue price of \$0.025 per Share. For every two shares issued under the Placement, investors will receive one free attaching unlisted option (subject to shareholder approval), exercisable at \$0.035 per option and expiring 15 October 2027 (**Options**).

The Company will issue 76.24m Placement Shares in Tranche 1 under the Company's available placement capacity under ASX Listing Rule 7.1 and ASX Listing Rule 7.1A and approximately 34.76m Placement Shares in Tranche 2, which is conditional on the Company obtaining shareholder approval at an extraordinary general meeting of shareholders to be held on or around 31 July 2026 (**EGM**). Approximately 55,500,000 free attaching Options are to be issued, subject to shareholder approval being obtained at the proposed EGM.

Notice under section 708A(5)(e) of the Corporations Act 2001 and for purposes of Share Purchase Plan

The Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Act**) in compliance with the requirements of section 708A(6) of the Act as follows:

1. On 2 June 2026 the Company issued 76,240,000 fully paid ordinary shares in the Company (**Shares**) without disclosure to investors under Part 6D.2 of the Act, with 45,733,890 Shares being issued within the ASX Listing Rule 7.1 capacity and 30,506,110 Shares within the ASX Listing Rule 7.1A capacity.
2. As at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. the provisions of section 674 of the Act.
3. The Company is not aware of any information required to be disclosed for the purposes of section 708A(6)(e) of the Act, being information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the Listing Rules of the ASX; and
 - b. that investors and their professional advisors would reasonably require for the purposes of making an informed assessment of:

- i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
- ii. the rights and liabilities attaching to the ordinary shares of the Company.

An Appendix 2A in respect of the Shares issued has been lodged today.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and demand for natural insecticides. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health, animal health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.
